Furthermore, the study of organoid cultures of human prostatic cell lines — either through genetic knockdown or use of Rac1 inhibitor, NSC23766 — allowed us to begin initial investigations on the biology of the TIAM1/RAC1 signaling pathway in BPH, with the results from these models corroborated in PDOs. Here, RAC1 is linked to benign prostatic hyperplasia.